PCX 12
Alternative Names: Encapsulated interleukin-12 vaccine - Therapyx; PCX-12Latest Information Update: 28 May 2025
At a glance
- Originator TherapyX
- Developer TherapyX; University of Rochester
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Interleukins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Prostate cancer
- No development reported Glioblastoma; Pancreatic cancer
Most Recent Events
- 28 May 2025 No recent reports of development identified for preclinical development in Glioblastoma in USA (Intratumoural)
- 28 Jun 2024 No recent reports of development identified for preclinical development in Pancreatic-cancer in USA (Intratumoural, Controlled release)
- 25 Jan 2024 University of Rochester plans a phase I trial for Pancreatic cancer (Late-stage disease, Second-line therapy or greater) in the US (Intratumoural, Injection) in October 2024 (NCT06217666)